Research company in cancer treatment with cellular immunotherapy, with aim to provide a better treatment for patients with their lead product Procure and to avoid chemotherapy.
Details: Innovative cellular immunotherapy represents a technology platform applicable for all solid tumors in general. Besides targeting ovarian cancer Procure can be developed in additional cancer indications with potential for further pipeline products. Advantages of cellular immunotherapies are that they are personalized therapy. The immune system is activated through cells originally taken from the individual patient, which reduces risks of intolerance. The therapy is invasive to a minimal extent.
URL: www.cellmed.eu
Category: Cancer
|
